Family of peptides synthesized in the human body have anticancer effects

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1459-1466

  Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Oncogenes; Review; Signal transducer and activator of transcription 3; Vascular endothelial growth factor; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA CATENIN; GUANOSINE TRIPHOSPHATE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 9; PEPTIDE; PROTEIN KINASE B; SECRETED FRIZZLED RELATED PROTEIN 3; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; FRIZZLED RELATED PROTEIN 3; FRIZZLED RELATED PROTEIN-3; ONCOPROTEIN; PROTEIN; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; GENE ACTIVATION; GENE EXPRESSION; HUMAN; MOUSE STRAIN; NONHUMAN; ONCOGENE; ONCOGENE C FOS; PANCREAS ADENOCARCINOMA; PEPTIDE SYNTHESIS; PROTEIN FAMILY; PROTO ONCOGENE; SMALL CELL LUNG CANCER; VESSEL DILATOR; WNT SIGNALING PATHWAY; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-3; Β-CATENIN;

ONCOGENES; REVIEW; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-3; VASCULAR ENDOTHELIAL GROWTH FACTOR; Β-CATENIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PEPTIDE BIOSYNTHESIS; PEPTIDES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTORS; WNT SIGNALING PATHWAY;

EID: 84902245906     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr., McCormick MT, Rodriguez-Paz G and Shocken DD: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90: 1129-1140, 1994.
2. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr., McCormick MT, Rodriguez-Paz G and Schocken DD: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 78: 1128-1134, 1994.
3. Vesely DL: Natriuretic Hormones. In: Seldin and Giebisch's The Kidney: Physiology and Pathophysiology, Fifth Edition. Alpern RJ, Caplan M, and Moe OW (eds.). San Diego, CA: Elsevier, Academic Press, pp. 1241-1281, 2013.
4. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G and Schocken DD: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 98: 323-329, 1998.
5. Vesely DL, Dietz JR, Parks JR, Antwi EK, Overton RM, McCormick, MT, Cintron G and Schocken DD: Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J 138: 625-632, 1999.
6. Clark LC, Farghaly H, Saba SR and Vesely DL: Amelioration with vessel dilator of acute tubular necrosis and renal failure established for two days. Am J Physiol 278: H1555-H1564, 2000.
7. Vesely DL: Natriuretic peptides and acute renal failure. Am J Physiol 285: F167-F177, 2003.
8. Brenner BM, Ballermann BJ, Gunning ME and Ziedel ML: Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70: 665-699, 1990.
9. Gardner DG, Kovacic-Milivojevic BK and Garmai M: Molecular biology of the natriuretic peptides. In: Atrial Natriuretic Peptides. Vesely DL (ed.) Trivandum, India: Research Signpost pp. 15-38, 1997.
10. Vesely DL: Atrial Natriuretic Hormones. Englewood Cliffs, NJ: Prentice Hall, pp. 1-256, 1992.
11. Schulz-Knappe P, Forssmann K, Herbst E, Hock D, Pipkorn R and Forssman WG: Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 66: 752-759, 1988.
12. Schermuly RT, Weissman N, Enke B, Ghofrani HA, Forssmann WG, Grimminger F, Seeger W and Walmarth D: Urodilatin, a natriuretic stimulating guanylate cyclase, and the phosphodiase five inhibitor dipyridamole attenuate experimental pulmonary hypertension. Am J Respir Cell Mol Biol 25: 219-225, 2001.
13. Nakao K, Ogawa Y, Suga S and Imura H: Molecular biology and biochemistry of the natriuretic peptide system. I. Natriuretic peptides. J Hypertens 10: 907-912, 1992.
14. Schweitz H, Vigne P, Moinier D, Frelin C and Lazdunski M: A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis augusticeps). J Biol Chem 267: 13928-13932, 1992.
15. Vesely BA, McAfee Q, Gower WR Jr. and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003.
16. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SR, Gower WR Jr. and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005.
17. Vesely BA, Alli AA, Song S, Gower WR Jr., Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.
18. Gower WR Jr., Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3',5'-cyclic monophosphate. Int J Gastrointestinal Cancer 36: 77-87, 2006.
19. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 36: 810-819, 2006.
20. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy 5: 97-104, 2007.
21. Eichelbaum EJ, Vesely BA, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones decrease up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine 30: 325-332, 2006.
22. Vesely BA, Alli A, Song S, Sanchez-Ramos, J, Fitz SR, Gower WR Jr. and Vesely DL: Primary malignant tumors of the heart: Four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology 105: 226-233, 2006.
23. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci 334: 342-349, 2007.
24. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones eliminate four-fold more human glioblastoma cells than green mamba snake peptide. Cancer Lett 254: 94-101, 2007.
25. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Gower WR Jr. and Vesely DL: Five cardiac hormones decrease the number of human small-cell lung cancer cells. Eur J Clin Invest 35: 388-398, 2005.
26. Vesely BA, Fitz SR, Gower WR Jr. and Vesely DL: Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells. Cancer Lett 233: 226-231, 2006.
27. Vesely DL: New anticancer agents: Hormones made within the heart. Anticancer Res 32: 2515-2522, 2012.
28. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL and Gower WR Jr.: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21: 445-452, 2007.
29. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. and Vesely DL: Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 38: 562-570, 2008.
30. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA and Gower WR Jr.: Four cardiac hormones eliminate up to twothirds of human breast cancers in athymic mice. In Vivo 21: 973-978, 2007.
31. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 29: 971-975, 2009.
32. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 29: 1889-1893, 2009.
33. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit MEK-1/2 activation in human prostate cancer cells. Anticancer Res 27: 1387-1392, 2007.
34. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK-1/2 activation in human prostate cancer cells. Anticancer Res 27: 3813-3818, 2007.
35. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK-1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006.
36. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK-1/2 in prostate cancer cells. Anticancer Res 26: 4143-4148, 2006.
37. Lane ML, Santana O, Frost CD, Nguyen J, Guerrero J, Skelton WP IV, Skelton M and Vesely DL: Cardiac hormones are c-JUN- N -Terminal Kinase 2-Inhibiting peptides. Anticancer Res 32: 721-726, 2012.
38. Derijard R, Hibi M, Wu IH, Barrett T, Su B, Teng TL, Karin M and Davis RJ: Unk1 - a protein-kinase stimulated by UV-light and Ha-Ras that binds and phosphorylates the c-JUN activation domain. Cell 76: 1025-1037, 1994.
39. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL and Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases for RAF-1 and MEKK. Science 266: 1719-1723, 1994.
40. Bienz M and Clevers H: Linking colorectal cancer to WNT signaling. Cell 103: 311-320, 2000.
41. Polakis P: Drugging WNT signaling in cancer. EMBO Journal 31: 2737-2746, 2012.
42. Li J, Mizukami Y, Zhang X, Jo W-S and Chung DC: Oncogenic KRAS stimulates WNT signaling in colon cancer through inhibition of GS-3β. Gastroenterology 128: 1907-1918, 2005.
43. Okada R, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T and Kerbel RS: Impact of oncogenes in tumor angiogenesis mutant KRAS up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95: 3609-3614, 1998.
44. Skelton WP IV, Skelton M and Vesely DL: Cardiac hormones are novel inhibitors of WNT-3a in human cancer cells. Cancer Therapy 9: 24-29, 2013.
45. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 295: 1182-1186, 1971.
46. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Reviews 25: 581-611, 2004.
47. Liotta LA, Kleinerman J and Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1004.
48. Hoeben A, Landuyt B, Highley MS, Wilders H, Van Oosterom AT and DeBruijn EA: Vascular endothelium growth factor. Pharmacological Rev 56: 549-580, 2004.
49. Folkman J: Angiogenesis: an organizing principle for drug discovery. Nature Reviews. Drug Discovery 6: 273-286, 2007.
50. Doanes AM, Hegland DD, Sethi R, Kovesdi I, Bruder JT and Finkel T: VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Bioph Res Commun 255: 545-548, 1999.
51. Meadows KN, Bryant P and Pumiglia K: Vascular endothelial growth factor induction of the angiogenic phenotype requires RAS activation. J Biol Chem 276: 49289-49298, 2001.
52. Byrne AM, Bouchier-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794.
53. Wang K, Jiang YZ, Chen DB and Zheng J: Hypoxia enhances FGF-2 and VEGF stimulated human placental artery endothelial cell proliferation: roles of MEK-1/2/ERK1-2 and PI3K/AKT1 pathways. Placenta 30: 1045-1051.
54. Gupta I, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PW and Hebbel SP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MNAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247: 495-504, 1999.
55. Breslin JW, Pappas PJ, Cerveira JJ, Hobson RW II and Duran WN: VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol 284: H92-H100, 2003.
56. McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist 5: S3-S10, 2000.
57. Nguyen JP, Frost CD, Lane ML, Skelton WR IV, Skelton M and Vesely DL: Novel dual inhibitors of vascular endothelial growth factor and the VEGFR2 Receptor. Eur J Clin Invest 42: 1061-1067, 2012.
58. Zhang X, Gaspard JP and Chung DC: Regulation of vascular endothelial growth factor by the WNT and KRAS pathways in colonic neoplasia. Cancer Res 61: 6050-6054, 2001.
59. Lowe AW, Olsen M, Hao Y, Lee SP, Lee KT, Chen X, Vanderijn M and Brown PO: Gene expression patterns in pancreatic tumor, cells and tissues. Ann Surg Oncol 10: 284-290, 2003.
60. Heiser PW, Cano DA, Landsman L, Kim GE, Kench JG, Klimstra DS, Taketo MM, Biankin AV and Hebrok M: Stabilization of β-Catenin induces pancreas tumor formation. Gastroenterology 135: 1288-1300, 2008.
61. Mirabelli-Primidahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bayat D, Gallinger S and Redston M: β-Catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59: 3346-3351, 1999.
62. Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi JK and Tomita Y: Altered expression of β-Catenin in renal cell cancer and transitional cell cancer with the absence of β-Catenin gene mutations. Clin Cancer Res 6: 460-466, 2000.
63. Maiti S, Alam R, Amos CI and Huff V: Frequent association of β-catenin and WTI mutations in Wilms tumors. Cancer Res 60: 6288-6292, 2000.
64. Ebert MPA, Yu J, Hoffman J, Rocco A, Rocken C, Kahmann S, Muller O, Korc M, Sung JJ and Malftheiner P: Loss of β-Catenin expression in metastatic gastric cancer. J Clin Oncol 2003: 1708-1714, 2003.
65. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC: β-catenin is a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262-4266, 2000.
66. Geyer FC, Lacrois-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho JS: β-Catenin pathway activation in breast cancer is associated with triplenegative phenotype but not with CTNNB1 mutation. Modern Pathol 24: 209-231, 2010.
67. Thompson MD and Monga SPS: WNT/β-Catenin signaling in liver health and disease. Hepatology 45: 1298-1305, 2007.
68. Morin PJ: β-Catenin signaling and cancer. BioEssays 21: 1021-1030, 1999.
69. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangui ML and Rimm DL: Frequent mutation and nuclear localization of β-Catenin in anaplastic thyroid carcinoma. Cancer Res 59: 1811-1815, 1999.
70. Abbosh PH and Nephew KP: Multiple signaling pathways converge on β-Catenin in thyroid cancer. Thyroid 15: 551-560, 2005.
71. Voeller JH, Trucia CI and Gelmann EP: β-Catenin mutations in human prostate cancer. Cancer Res 58: 2520-2523, 1998.
72. Cheshire DR and Isaacs WB: β-Catenin signaling prostate cancer: an early perspective. Endocr-Relat Cancer 10: 537-560, 2003.
73. Skelton WP, Skelton M and Vesely DL: Role of β-Catenin in the anticancer effects of cardiac hormones. Anticancer Res 33: 2409-2414, 2013.
74. Serafino A, Moroni N, Psaila R, Zonfrillo M, Andreola F, Wannenes F, Mercuri L, Rasi G and Pierimarchi P: Antiproliferative effect of atrial natriuretic peptide on colorectal cancer cells: Evidence for an Akt-mediated cross-talk between NHE-1 activity and WNT/β-Catenin signaling. Biochim Biophys Acta 1822: 1004-1018, 2012.
75. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Burh HJ and Hanski C: Target genes of β-Catenin-T cell factor/lymphoid-enhancer factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 96: 1603-1608, 1999.
76. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Reviews. Cancer 2: 489-501, 2002.
77. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Nature Reviews. Cancer 24: 7455-7464, 2005.
78. Hay N: The AKT-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183, 2005.
79. Hennessy GT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev. Drug Discovery 4: 988-1004, 2005.
80. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 441: 424-430, 2006.
81. Staal SP, Hartley JW and Rowe SP: Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 74: 3065-3067.
82. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205, 2002.
83. Skelton WP IV, Skelton M and Vesely DL: Inhibition of Akt in human pancreatic, renal and colorectal cancer cells by four cardiac hormones. Anticancer Res 33: 785-790, 2013.
84. Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Therap 6: 2139-2148, 2007.
85. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/AKT signal transduction pathway: requirement for FLK-1/KDR activation. J Biol Chem 273: 30336-30343, 1998.
86. Amaravadi R and Thomopson CB: The surval kinases AKT and Pim as potential pharmacological target. J Clin Invest 115: 2618-2624, 2005.
87. Lin K, Wang S, Julius MA, Kitajewski J, Moos M Jr. and Luyten SP: The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of WNT signaling. Proc Natl Acad Sci USA 94: 11196-11200, 1997.
88. Rattner A, Hsieh JC, Smallwood PM, Gilbert DJ, Copeland NG, Jenkins NA and Nathans J: A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA 94: 2859-2863, 1997.
89. Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J and Leahy DJ: Insights into WNT binding and signaling from the structures of two frizzled cysteine-rich domains. Nature 412: 86-90, 2001.
90. Malbon CC: Frizzleds: New members of the superfamily of G-protein-coupled receptors. Frontiers in Bioscience 9: 1048-1058, 2004.
91. Hirata H, Hinoda Y, Ueno K, Majid S, Saini S and Dahiya R: Role of secreted frizzled-related protein 3 in human renal cell carcinoma. Cancer Res 70: 1896-1905, 2010.
92. Rubin JS, Barshishat-Kupper M, Feroze-Merzoup F and Xi ZF: Secreted WNT antagonists are tumor suppressors: pro and con. Frontiers in Bioscience 11: 2093-2105, 2006.
93. Xu YK and Nusse R: The frizzled CRD domain is conserved in diverse proteins including several receptor tyrosine kinases. Current Biol 8: R405-R406, 1998.
94. Kawano Y and Kypta R: Secreted antagonists of the WNT signalling pathway. J Cell Sci 116: 2627-2634, 2003.
95. Skelton WP IV, Skelton M and Vesely DL: Cardiac hormones are potent inhibitors of secreted Frizzled related protein-3 in human cancer cells. Exp Ther Med 5: 475-478, 2013.
96. Schindler C, Shuai K, Prezioso VR and Darnell JE Jr.: Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257: 809-813, 1992.
97. Yu H and Jove R: The STATs of cancer: New molecular targets come of age. Nature Reviews. Cancer 4: 450-456, 2004.
98. Darnell JR Jr.,: Transcription factors as targets for cancer therapy. Nature Reviews. Cancer 2: 740-749, 2002.
99. Bromberg J and Darnell JE Jr.: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473, 2002.
100. Grandis J, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of STAT3 but not STAT1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102: 1385-1392, 1998.
101. Song L, Turkson J, Karras JG, Jove R and Haura EG: Activation of STAT3 by receptor tyrosine kinases and cytokinases regulates survival in human non-small-cell carcinoma cells. Oncogene 22: 4150-4165, 2003.
102. Chung J, Uchida E, Grammer TC and Blenis J: STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 17: 6508-6516, 1997.
103. Lane ML, Frost CD, Nguyen JP, Skelton WP IV, Skelton M and Vesely DL: Potent selective inhibition of STAT3 versus STAT1 by cardiac hormones. Mol Cell Biochem 371: 209-215, 2012.
104. Muller R, Bravo R, Burckhardt J and Curran T: Induction of c-FOS gene and protein by growth factors precedes activation of c-Myc. Nature 312: 716-720, 1984.
105. Shaulian E and Karin M: AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001.
106. Sagar S, Edwards R and Sharp F: Epidermal growth factor and transforming growth factor α induce c-FOS gene expression in retinal Muller cells in vivo. J Neurosci Res 29: 549-559, 1991.
107. Guller M, Toualbi-Abed K, Legand A, Michel L, Mauviel A, Bernuau D and Daniel F: c-FOS overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin-D1. World J Gastroenterol 14: 6339-6346, 2008.
108. Arbuthnot P, Kew M and Fitschen W: c-FOS and c-Myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res 11: 921-924, 1991.
109. Bolak J, Meier T, Halter R, Spanel R and Spanel-Borowski K: Epidermal growth factor-induced hepatocellular carcinoma: Gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24: 1809-1819, 2005.
110. Yuen MF, Wu PC, Lau JYN and Lai CL: Expression of c-Myc, c-FOS and c-JUN in hepatocellular carcinoma. Cancer 91: 106-112, 2001.
111. Halazonetis TD, Georgopoulos K, Greenberg ME and Leder P: c-JUN dimerizes with itself and c-FOS, forming complexes of different DNA-binding proteins. Cell 55: 917-924, 1988.
112. Rauscher F, Cohen D, Curran T, Bos T, Vogt P, Bohmann D, Tijan R and Franza BR Jr.: Fos-associated protein p39 is the product of the jun proto-oncogene. Science 240: 1010-1016, 1988.
113. Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD and Gutkind JS: Regulation of the transcriptional activity of c-FOS by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 280: 35081-35084, 2005.
114. Feng DY, Zheng H, Tan Y and Cheng RX: Effect of phosphorylation of MAPK and STAT-3 and expression of c-FOS and c-JUN proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 7: 33-36, 2001.
115. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M and Davis RJ: JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-JUN activation domain. Cell 76: 1025-1037, 1994.
116. Zhang X, Wrzeszczynska MH, Horvath CM and Darnell JE: Interacting regions in STAT-3 and c-JUN that participate in cooperative transcriptional activation. Mol Cell Biol 19: 7138-7146, 1999.
117. Saba SR, Garces AH, Clark LC, Soto J, Gower WR Jr., and Vesely DL: Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 53: 989-995, 2005.
118. Saba SR and Vesely DL: Cardiac natriuretic peptides: Hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers. Histol Histopath 21: 775-783, 2006.
119. Manimala NJ, Frost CD, Lane ML, Higuera M, Beg R and Vesely DL: Anticancer peptides from the heart target c-JUN and c-FOS in hepatocellular, small-cell lung and renal carcinomas. Eur J Clin Invest 43: 1156-1162, 2013.
120. Sun Y, Eichelbaum EJ, Lenz A, Wang H and Vesely DL: Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. Eur J Clin Invest 40: 408-413, 2010.